Literature DB >> 29396106

The prevalence of central hypertension defined by a central blood pressure type I device and its association with target organ damage in the community-dwelling elderly Chinese: The Northern Shanghai Study.

Shikai Yu1, Jing Xiong1, Yuyan Lu1, Chen Chi1, Jiadela Teliewubai1, Bin Bai1, Hongwei Ji1, Yiwu Zhou1, Ximin Fan1, Jacques Blacher2, Jue Li3, Yi Zhang4, Yawei Xu5.   

Abstract

We aimed to investigate the prevalence of central hypertension and its association with target organ damage (TOD). 1983 community-dwelling elderly Chinese people were recruited for this analysis. Brachial and central blood pressure (BP) were measured by an oscillometric device and SphygmoCor (type I device), respectively. Brachial hypertension was defined by brachial systolic BP/diastolic BP ≥140/90 mmHg or using antihypertensive medications. Central hypertension was defined by central systolic BP/diastolic BP ≥130/90 mmHg or using antihypertensive medications. TOD included left ventricular hypertrophy and diastolic dysfunction, carotid-femoral pulse wave velocity, and urinary albumin-creatinine ratio. In this cohort, there were 563 (28.4%) brachial and central consistent normotension, 46 (2.3%) isolated brachial hypertension, 27 (1.4%) isolated central hypertension, and 1347 (67.9%) brachial and central combined hypertension (BCCH). In analysis of variance, BCCH showed significantly higher levels in all TOD than brachial and central consistent normotension. In multiple logistic regression, all TOD were significantly associated with BCCH (left ventricular hypertrophy: adjusted odds ratios [95% confidence interval] = 2.03 [1.55, 2.68]; left ventricular diastolic dysfunction: 2.29 [1.53, 3.43]; carotid-femoral pulse wave velocity >10 m/s: 3.41 [2.55, 4.58]; urinary albumin-creatinine ratio >30 mg/g: 1.97 [1.58, 2.44]), rather than isolated brachial hypertension or isolated central hypertension. In conclusion, central hypertension was prevalent (69.3%) in this elderly cohort. BCCH was independently and significantly associated with cardiac, arterial, and renal damage. This finding implies that both brachial and central BPs need to be considered for managing hypertension.
Copyright © 2018 American Society of Hypertension. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Carotid-femoral pulse wave velocity; central blood pressure; left ventricular diastolic dysfunction; left ventricular hypertrophy; target organ damage; urinary albumin-creatinine ratio

Mesh:

Year:  2018        PMID: 29396106     DOI: 10.1016/j.jash.2017.12.013

Source DB:  PubMed          Journal:  J Am Soc Hypertens        ISSN: 1878-7436


  5 in total

1.  Central blood pressure for the management of hypertension: Is it a practical clinical tool in current practice?

Authors:  Hao-Min Cheng; Shao-Yuan Chuang; Tzung-Dau Wang; Kazuomi Kario; Peera Buranakitjaroen; Yook-Chin Chia; Romeo Divinagracia; Satoshi Hoshide; Huynh Van Minh; Jennifer Nailes; Sungha Park; Jinho Shin; Saulat Siddique; Jorge Sison; Arieska Ann Soenarta; Guru Prasad Sogunuru; Apichard Sukonthasarn; Jam Chin Tay; Boon Wee Teo; Yuda Turana; Narsingh Verma; Yuqing Zhang; Ji-Guang Wang; Chen-Huan Chen
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-12-16       Impact factor: 3.738

2.  Ambulatory blood pressure phenotypes and isolated elevation of office central or brachial blood pressure.

Authors:  Audes D M Feitosa; Annelise M G Paiva; Marco A Mota-Gomes; Andréa A Brandão; Andrei C Sposito; Wilson Nadruz
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-08-27       Impact factor: 3.738

3.  Parameters of Central Hemodynamics as New Biomarkers of Cardiovascular Risk.

Authors:  José Fernando Vilela-Martin
Journal:  Arq Bras Cardiol       Date:  2020-12       Impact factor: 2.000

4.  Risk Stratification by Cross-Classification of Central and Brachial Systolic Blood Pressure.

Authors:  Yi-Bang Cheng; Lutgarde Thijs; Lucas S Aparicio; Qi-Fang Huang; Fang-Fei Wei; Yu-Ling Yu; Jessica Barochiner; Chang-Sheng Sheng; Wen-Yi Yang; Teemu J Niiranen; José Boggia; Zhen-Yu Zhang; Katarzyna Stolarz-Skrzypek; Natasza Gilis-Malinowska; Valérie Tikhonoff; Wiktoria Wojciechowska; Edoardo Casiglia; Krzysztof Narkiewicz; Jan Filipovský; Kalina Kawecka-Jaszcz; Ji-Guang Wang; Yan Li; Jan A Staessen
Journal:  Hypertension       Date:  2022-03-04       Impact factor: 10.190

Review 5.  Central hypertension is a non-negligible cardiovascular risk factor.

Authors:  Yi-Bang Cheng; Yan Li; Hao-Min Cheng; Saulat Siddique; Minh Van Huynh; Apichard Sukonthasarn; Chen-Huan Chen; Ji-Guang Wang
Journal:  J Clin Hypertens (Greenwich)       Date:  2022-09       Impact factor: 2.885

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.